The Cooling And Surviving Septic Shock Study (CASS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by Danish Procalcitonin Study Group
Sponsor:
Collaborators:
TRYG Foundation
Lundbeck Foundation
Information provided by (Responsible Party):
Danish Procalcitonin Study Group
ClinicalTrials.gov Identifier:
NCT01455116
First received: October 15, 2011
Last updated: September 23, 2013
Last verified: September 2013

October 15, 2011
September 23, 2013
November 2011
December 2016   (final data collection date for primary outcome measure)
Mortality [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
All cause
Same as current
Complete list of historical versions of study NCT01455116 on ClinicalTrials.gov Archive Site
  • Renal failure [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

    RIFLE criteria (R+I+F) eGFR decrease (ml/min/1.73 m2) eGFR decrease to <60 ml/min/1,73)

    + derivatives of the above

  • Respiratory [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

    Use of Mechanical Ventilation on day 4 No. of days where Mechanical Ventilation is used Delta PaO2/FiO2 ratio until day 4

    +Derivatives of the above

  • Circulatory breakdown/Septic Shock [ Time Frame: Measure on day 4 ] [ Designated as safety issue: Yes ]
    Delta MAP days 1-4 Inotropic Score day 1-4 Achieved discontinuation of inotropics on day 4
  • Cerebral dysfunction [ Time Frame: Day 1-4 ] [ Designated as safety issue: Yes ]
    Delta RASS 1-4 CAM-ICU: Days with positive CAM-ICU within 72 h after awakening MiniMentalState Examination (MMSE)
  • Hepatic Failure [ Time Frame: Days 1-4 ] [ Designated as safety issue: Yes ]
    Delta Bilirubin 1-4 Fraction of subjects with Bilirubin level >21 micromoles/L on day 4
  • Coagulatory Failure [ Time Frame: Until Day 4/10 ] [ Designated as safety issue: Yes ]
    Delta Platelets day 1-4 Delta INR days 1-4 (and factor 2/7/10) Delta APTT (days 1-4) Total consumption of SAG-M on days 1-10 Occurrence of Severe bleeding (surgery demanding or CT-verified, fresh upper or lower G-I bleeding) Thromboelastography
  • Duration of clinical infection [ Time Frame: Days 1-4 + 1-30 ] [ Designated as safety issue: Yes ]
    Delta C-reactive protein day 1-4 Achieved decrease in CRP >30 % from day 1-4 PCT decrease (Quantitative) day 1-10
  • Number of days Free of Organ failure [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

    Number of days Free of Organ failure until day 30:

    Need for Mechanical ventilation, need for inotropic, RIFLE criteria positive, positive CAM-ICU days.

  • Renal failure [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

    RIFLE criteria (R+I+F) eGFR decrease (ml/min/1.73 m2) eGFR decreae to <60 ml/min/1,73)

    + derivatives of the above

  • Respiratory [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

    Use of Mechanical Ventilation on day 4 No. of days where Mech Ventilation is used Delta PaO2/FiO2 ratio until day 4

    +Derivatives of the above

  • Circulatory breakdow/Septic Shock [ Time Frame: Measure on day 4 ] [ Designated as safety issue: Yes ]
    Delta MAP days 1-4 Inotropic Score day 1-4 Achieved discontinuation of inotropics on day 4
  • Cerebral dysfunction [ Time Frame: Day 1-4 ] [ Designated as safety issue: Yes ]
    Delta RASS 1-4 CAM-ICU: Days with positive CAM-ICU within 72 h after awakening MiniMentalState Examination (MMSE)
  • Hepatic Failure [ Time Frame: Days 1-4 ] [ Designated as safety issue: Yes ]
    Delta Bilirubin 1-4 Fraction of subjects with Bilirubin level >21 mmoles/L on day 4
  • Coagulatory Failure [ Time Frame: Until Day 4/10 ] [ Designated as safety issue: Yes ]
    Delta Platelets day 1-4 Delta INR days 1-4 (and factor 2/7/10) Delta APTT (days 1-4) Total consumption of SAG-M on days 1-10 Occurrence of Severe bleeding (surgery demanding or CT-verified, fresh upper or lower G-I bleeding) Thromboelastorgraphy
  • Duration of clinical infection [ Time Frame: Days 1-4 + 1-30 ] [ Designated as safety issue: Yes ]
    Delta C-reactive protein day 1-4 Achived decrease in CRP >30 % from day 1-4 PCT decrease (Quantitative) day 1-10
  • Number of days Free of Organ failure [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

    Number of days Free of Organ failure until day 30:

    Need for Mech. ventilation, need for inotropic, RIFLE criteria positive, positive CAM-ICU days.

Not Provided
Not Provided
 
The Cooling And Surviving Septic Shock Study (CASS)
Randomized Trial to Determine Whether Mild Induced Hypothermia Can Reduce Mortality in Adult Patients With Septic Shock

Septic shock is in critically ill patients is a condition associated with a high rate of organ failure and hereto attributable mortality ~45-55% Hypothesis: Mild Induced Hypothermia reduces the mortality of critically ill patients with septic shock by reducing organ metabolism, counteracting on microcirculatory thrombosis, genetically downregulating tissue apoptosis and by reducing bacterial growth rate and toxin production.

Septic shock is an acute life-threatening condition, with great organ damage for every hour. The patients have a high risk of dying and therefore rapid treatment is of crucial importance for survival of the patients.

Septic shock is mainly due to a collapse in the blood circulation (the capillary system) due to blockage by blood cells - a process initiated by substances from the cells of the immune system via activation of coagulation. The normal function of the smallest blood vessels is to transport oxygen, nutrients and drugs to organs and tissues, and lead waste products away. While the offer of oxygen and nutrients to the organs decreases, the consumption of oxygen and nutrients increases due to fever and immune reactions.

When the capillary system collapses, the organs and tissues suffer, and various forms of cell death in the organs begins including "programmed cell death" ("apoptosis"). This leads to organ damage, for example brain damage or kidney damage and ultimately to multiple organ dysfunction which is the direct cause of the patient dies.

Mild induced hypothermia (cooling to 32 0C-34 0C) affects at least 5 core areas in the pathophysiology of septic shock: 1) inhibition of inflammation 2) inhibition of apoptosis ("programmed cell death"), 3) antithrombotic, 4) decreases the metabolism and 5) inhibits bacterial growth and production of toxins.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Septic Shock
Procedure: Mild Induced Hypothermia
Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
Other Name: Cooling
  • Experimental: Mild induced hypothermia
    Induced hypothermia to 32-34 degrees Celsius (90 - 93 degrees Fahrenheit)
    Intervention: Procedure: Mild Induced Hypothermia
  • No Intervention: Fever Respect
    Standard of care septic shock therapy according to Surviving Sepsis Campaign guidelines
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
560
December 2016
December 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Aged > 50 years of age.
  2. Severe sepsis /septic shock = SIRS + suspected infection+hypotension Mean Arterial Blood Pressure (MAP) <70 mmHg,
  3. Admitted to the participating intensive care units (ICU)
  4. Indication for intubation
  5. Possibility of inclusion within 6 hours after septic shock/severe sepsis is diagnosed in the ICU. Patients admitted with septic shock/severe sepsis should be included within 6 hours after admission. If a patient is not included within this period, that patient cannot be included within the same hospitalization.
  6. The patient must have an expected stay in the ICU of more than 24 hours. Anticipated death within 24 hours after admission to the ICU does not exclude participation; however no decision of reduction of treatment level must have been taken. During this time period, probability that the patient is discharged to a floor department must not be likely (<10% probability).

Exclusion Criteria:

  1. Patients are pregnant or breast feeding
  2. The findings of the initial screening, shows that the patient has a bleeding disorder and/or the patient has an uncontrollable bleeding and /or surgery within the last 24 hours
  3. Persons who are detained under the Act on the use of coercion in psychiatry
Both
50 Years and older
No
Contact: Jens Ulrik S Jensen, MD, PhD +4528938168 juj@cphiv.dk
Contact: Maria E Johansen, MD +4535455757 mej@cphiv.dk
Denmark
 
NCT01455116
H-A-2008-086
Yes
Danish Procalcitonin Study Group
Danish Procalcitonin Study Group
  • TRYG Foundation
  • Lundbeck Foundation
Study Director: Jens Ulrik S Jensen, MD, PhD Copenhagen HIV Programme, University of Copenhagen
Danish Procalcitonin Study Group
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP